The Dubowitz Neuromuscular Centre, UCL Institute of Child Health, London, United Kingdom.
PLoS One. 2011 Mar 9;6(3):e17454. doi: 10.1371/journal.pone.0017454.
Stem cell transplantation is a promising potential therapy for muscular dystrophies, but for this purpose, the cells need to be systemically-deliverable, give rise to many muscle fibres and functionally reconstitute the satellite cell niche in the majority of the patient's skeletal muscles. Human skeletal muscle-derived pericytes have been shown to form muscle fibres after intra-arterial transplantation in dystrophin-deficient host mice. Our aim was to replicate and extend these promising findings.
METHODOLOGY/PRINCIPAL FINDINGS: Isolation and maintenance of human muscle derived cells (mdcs) was performed as published for human pericytes. Mdscs were characterized by immunostaining, flow cytometry and RT-PCR; also, their ability to differentiate into myotubes in vitro and into muscle fibres in vivo was assayed. Despite minor differences between human mdcs and pericytes, mdscs contributed to muscle regeneration after intra-muscular injection in mdx nu/nu mice, the CD56+ sub-population being especially myogenic. However, in contrast to human pericytes delivered intra-arterially in mdx SCID hosts, mdscs did not contribute to muscle regeneration after systemic delivery in mdx nu/nu hosts.
CONCLUSIONS/SIGNIFICANCE: Our data complement and extend previous findings on human skeletal muscle-derived stem cells, and clearly indicate that further work is necessary to prepare pure cell populations from skeletal muscle that maintain their phenotype in culture and make a robust contribution to skeletal muscle regeneration after systemic delivery in dystrophic mouse models. Small differences in protocols, animal models or outcome measurements may be the reason for differences between our findings and previous data, but nonetheless underline the need for more detailed studies on muscle-derived stem cells and independent replication of results before use of such cells in clinical trials.
干细胞移植是肌肉萎缩症的一种很有前途的潜在治疗方法,但为此目的,细胞需要能够全身递送,能够产生许多肌肉纤维,并在大多数患者的骨骼肌中重建卫星细胞龛。已经证明,人类骨骼肌衍生的周细胞在肌营养不良缺陷宿主小鼠的动脉内移植后可以形成肌肉纤维。我们的目的是复制和扩展这些有希望的发现。
方法/主要发现:如已发表的用于人类周细胞的方法,进行人类肌肉来源细胞(mdc)的分离和维持。通过免疫染色、流式细胞术和 RT-PCR 对 mdc 进行特征描述;还检测了它们在体外分化为肌管和在体内分化为肌肉纤维的能力。尽管人类 mdc 和周细胞之间存在微小差异,但 mdc 仍能在 mdx nu/nu 小鼠的肌肉内注射后促进肌肉再生,其中 CD56+亚群尤其具有成肌能力。然而,与在 mdx SCID 宿主的动脉内递送的人类周细胞不同,mdc 不能在 mdx nu/nu 宿主的全身递送后促进肌肉再生。
结论/意义:我们的数据补充和扩展了以前关于人类骨骼肌衍生干细胞的发现,并清楚地表明,需要进一步工作来从骨骼肌中制备纯细胞群体,这些细胞在培养中保持其表型,并在肌营养不良小鼠模型的全身递送后对骨骼肌再生做出稳健贡献。方案、动物模型或结果测量方面的微小差异可能是我们的发现与以前数据之间存在差异的原因,但仍需要对肌肉衍生干细胞进行更详细的研究,并在临床试验中使用这些细胞之前对结果进行独立复制。